Radiation Dosimetry of 99mTc-PSMA I&S a single-center prospective study /
Introduction: Tc-99m-labeled Mas3-y-nal-k(Sub-KuE) (Tc-99m-PSMA I&S) is a prostate specific membrane antigen (PSMA) tracer that can be used for planar and SPECT/CT gamma imaging and radio-guided surgery (RGS). The primary aim of this study was to estimate the dosimetry of Tc-99m-PSMA I&S usi...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2021
|
| Sorozat: | JOURNAL OF NUCLEAR MEDICINE
62 No. 8 |
| Tárgyszavak: | |
| doi: | 10.2967/jnumed.120.253476 |
| mtmt: | 31869299 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/26543 |
| LEADER | 03235nab a2200313 i 4500 | ||
|---|---|---|---|
| 001 | publ26543 | ||
| 005 | 20230220124028.0 | ||
| 008 | 230220s2021 hu o 0|| Angol d | ||
| 022 | |a 0161-5505 | ||
| 024 | 7 | |a 10.2967/jnumed.120.253476 |2 doi | |
| 024 | 7 | |a 31869299 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a Angol | ||
| 100 | 1 | |a Urbán Szabolcs | |
| 245 | 1 | 0 | |a Radiation Dosimetry of 99mTc-PSMA I&S |h [elektronikus dokumentum] : |b a single-center prospective study / |c Urbán Szabolcs |
| 260 | |c 2021 | ||
| 300 | |a 1075-1081 | ||
| 490 | 0 | |a JOURNAL OF NUCLEAR MEDICINE |v 62 No. 8 | |
| 520 | 3 | |a Introduction: Tc-99m-labeled Mas3-y-nal-k(Sub-KuE) (Tc-99m-PSMA I&S) is a prostate specific membrane antigen (PSMA) tracer that can be used for planar and SPECT/CT gamma imaging and radio-guided surgery (RGS). The primary aim of this study was to estimate the dosimetry of Tc-99m-PSMA I&S using a hybrid method (sequential gamma planar imaging and one single SPECT/CT) in healthy volunteers. The secondary aim was to depict the tracer biodistribution and tumor-to-background ratios (TBR) in patients with prostate cancer (PCa). Methods: Dosimetry of Tc-99m-PSMA I&S was investigated in four healthy volunteers. Whole-body planar imaging was acquired at 1, 2, 3, 6 and 24 hours, and SPECT/CT at 6h after tracer injection. Contours of organs were drawn on all acquisitions to determine organ activity at each timepoint. Absorbed dose was estimated using two Methods: 1) independent curve-fitting manual method (Levenberg-Marquardt-based algorithm using dose factors from Radiation Dose Assessment Resource (RADAR) web site) and 2) OLINDA/EXM® v 2.0 software (HERMES Medical Solutions). Biodistribution of Tc-99m-PSMA I&S was assessed in ten patients with PCa on SPECT/CT images at 6 h. Tumor uptake (SUVmax), and TBR (tumor SUVmax/ background organ SUVmean) using muscle (T/M), bladder (T/B) and intestine (T/I) as background organs were determined. Results: The mean injected activity of Tc-99m-PSMA I&S was 717 MBq (range: 562-828). No adverse events related to the injection of Tc-99m-PSMA-I&S were reported. The average radiation effective dose was 0.0055 mSv/MBq with the RADAR manual method and 0.0052 mSv/MBq with OLINDA/EXM®. Total body effective dose ranged between 3.33-4.42 and 3.11-4.23 mSv, respectively. All PCa patients showed high tracer uptake in primary and metastatic lesions with T/M, T/B, T/I ranging from 5.29 - 110, 0.11 - 7.02 and 0.96 - 16.30, respectively. Conclusion: Effective doses of Tc-99m-PSMA I&S were comparable to those known for most of the Tc-99m tracers and was lower than 68Ga-labelled and 18F-labelled agents. Tc-99m-PSMA I&S SPECT/CT showed high TBR in PCa patients. This study can provide required data for translation and approval of Tc-99m-PSMA I&S by regulatory agencies. | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 1 | |a Meyer Catherine |e aut |
| 700 | 0 | 1 | |a Dahlbom Magnus |e aut |
| 700 | 0 | 1 | |a Farkas István |e aut |
| 700 | 0 | 1 | |a Sipka Gábor |e aut |
| 700 | 0 | 1 | |a Besenyi Zsuzsanna |e aut |
| 700 | 0 | 1 | |a Czernin Johannes |e aut |
| 700 | 0 | 1 | |a Calais Jeremie |e aut |
| 700 | 0 | 1 | |a Pávics László |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/26543/1/31869299.pdf |z Dokumentum-elérés |